CN107849061B - H3K9me3调控用于增强认知功能的用途 - Google Patents

H3K9me3调控用于增强认知功能的用途 Download PDF

Info

Publication number
CN107849061B
CN107849061B CN201680040210.0A CN201680040210A CN107849061B CN 107849061 B CN107849061 B CN 107849061B CN 201680040210 A CN201680040210 A CN 201680040210A CN 107849061 B CN107849061 B CN 107849061B
Authority
CN
China
Prior art keywords
cognitive
effective amount
etp69
treatment
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680040210.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107849061A (zh
Inventor
卡尔·科特曼
拉里·奥弗曼
希哈·斯尼格扎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN107849061A publication Critical patent/CN107849061A/zh
Application granted granted Critical
Publication of CN107849061B publication Critical patent/CN107849061B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Networks Using Active Elements (AREA)
  • Amplifiers (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
CN201680040210.0A 2015-06-08 2016-06-03 H3K9me3调控用于增强认知功能的用途 Active CN107849061B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562172690P 2015-06-08 2015-06-08
US62/172,690 2015-06-08
PCT/US2016/035764 WO2016200690A1 (en) 2015-06-08 2016-06-03 USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION

Publications (2)

Publication Number Publication Date
CN107849061A CN107849061A (zh) 2018-03-27
CN107849061B true CN107849061B (zh) 2021-05-14

Family

ID=57504356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680040210.0A Active CN107849061B (zh) 2015-06-08 2016-06-03 H3K9me3调控用于增强认知功能的用途

Country Status (11)

Country Link
US (5) US10272093B2 (enExample)
EP (2) EP3733188B1 (enExample)
JP (1) JP6851081B2 (enExample)
KR (1) KR102776570B1 (enExample)
CN (1) CN107849061B (enExample)
AU (2) AU2016276172B2 (enExample)
CA (1) CA2988568A1 (enExample)
ES (2) ES2944446T3 (enExample)
IL (1) IL256055B (enExample)
MX (1) MX2017015909A (enExample)
WO (1) WO2016200690A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017015909A (es) * 2015-06-08 2018-05-07 Univ California Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva.
CN111032025A (zh) * 2017-06-20 2020-04-17 居里研究所 Suv39h1组蛋白甲基转移酶的抑制剂在癌症联合治疗中的用途
CN108434454B (zh) * 2018-03-16 2019-10-11 大连医科大学 Adar1在缓解认知功能障碍方面的应用
WO2020223475A1 (en) * 2019-05-02 2020-11-05 Board Of Regents, The University Of Texas System Methods and compositions involving tert activating therapies
US20240009203A1 (en) * 2020-08-03 2024-01-11 Cedars-Sinai Medical Center Compositions and methods for treating alzheimer's disease

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060019227A1 (en) * 2004-07-22 2006-01-26 Hardwicke Susan B Methods for cognitive treatment
US20060171938A1 (en) * 2005-02-03 2006-08-03 Stock Jeffry B Compositions and methods for enhancing cognitive function
CN101466365A (zh) * 2006-06-09 2009-06-24 惠氏公司 增强认知功能的方法
US20090216301A1 (en) * 2003-01-24 2009-08-27 Jackson Streeter Low level light therapy for enhancement of neurologic function
CN102271763A (zh) * 2008-12-03 2011-12-07 麻省理工学院 抑制hdac2以促进记忆
CN102858177A (zh) * 2010-03-04 2013-01-02 默沙东公司 儿茶酚-o-甲基转移酶抑制剂及其在治疗精神障碍中的用途
CN103189069A (zh) * 2010-09-13 2013-07-03 首尔大学校产学协力团 以miRNA为靶的神经退行性疾病的治疗
WO2014066435A1 (en) * 2012-10-22 2014-05-01 City Of Hope Etp derivatives
WO2015081166A1 (en) * 2013-11-26 2015-06-04 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009084271A (ja) * 2007-09-07 2009-04-23 Toyama Univ 脳由来神経栄養因子の発現誘導剤および発現誘導方法
CA2909506C (en) * 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder
MX2017015909A (es) * 2015-06-08 2018-05-07 Univ California Uso de la modulacion de trimetilacion de h3k9 (h3k9me3) para aumentar la funcion cognitiva.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090216301A1 (en) * 2003-01-24 2009-08-27 Jackson Streeter Low level light therapy for enhancement of neurologic function
US20060019227A1 (en) * 2004-07-22 2006-01-26 Hardwicke Susan B Methods for cognitive treatment
US20060171938A1 (en) * 2005-02-03 2006-08-03 Stock Jeffry B Compositions and methods for enhancing cognitive function
CN101466365A (zh) * 2006-06-09 2009-06-24 惠氏公司 增强认知功能的方法
CN102271763A (zh) * 2008-12-03 2011-12-07 麻省理工学院 抑制hdac2以促进记忆
CN102858177A (zh) * 2010-03-04 2013-01-02 默沙东公司 儿茶酚-o-甲基转移酶抑制剂及其在治疗精神障碍中的用途
CN103189069A (zh) * 2010-09-13 2013-07-03 首尔大学校产学协力团 以miRNA为靶的神经退行性疾病的治疗
WO2014066435A1 (en) * 2012-10-22 2014-05-01 City Of Hope Etp derivatives
WO2015081166A1 (en) * 2013-11-26 2015-06-04 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Exercise and Sodium Butyrate Transform a Subthreshold Learning Event into Long-Term Memory via a Brain-Derived Neurotrophic factor-Dependent Mechanism";Karlie A Intlekofer et al.;《Neuropsychopharmacology》;20130424;第38卷;第2027-2034页 *
"Inhibition of histone methyltransferases SUV39H1 and G9a leads to neuroprotection in an in vitro model of cerebral ischemia";Sophie Schweizer et al.;《Journal of Cerebral Blood Flow & Metabolism》;20150513;第35卷;第1640-1647页 *

Also Published As

Publication number Publication date
EP3733188B1 (en) 2023-01-25
IL256055A (en) 2018-01-31
KR20180014432A (ko) 2018-02-08
US20230057592A1 (en) 2023-02-23
ES2944446T3 (es) 2023-06-21
AU2016276172B2 (en) 2019-07-11
AU2016276172A1 (en) 2018-01-04
EP3733188A1 (en) 2020-11-04
EP3303347A4 (en) 2019-03-06
US20240374608A1 (en) 2024-11-14
US11311551B2 (en) 2022-04-26
WO2016200690A1 (en) 2016-12-15
MX2017015909A (es) 2018-05-07
EP3303347A1 (en) 2018-04-11
CA2988568A1 (en) 2016-12-15
AU2019246902A1 (en) 2019-10-31
US10849910B2 (en) 2020-12-01
US20180228808A1 (en) 2018-08-16
US20210106590A1 (en) 2021-04-15
CN107849061A (zh) 2018-03-27
IL256055B (en) 2022-06-01
US20190209577A1 (en) 2019-07-11
AU2019246902B2 (en) 2021-08-19
ES2807878T3 (es) 2021-02-24
EP3303347B1 (en) 2020-05-06
US10272093B2 (en) 2019-04-30
JP6851081B2 (ja) 2021-03-31
JP2018516940A (ja) 2018-06-28
KR102776570B1 (ko) 2025-03-04

Similar Documents

Publication Publication Date Title
US20240374608A1 (en) USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION
Snigdha et al. H3K9me3 inhibition improves memory, promotes spine formation, and increases BDNF levels in the aged hippocampus
Gong et al. GW9508 ameliorates cognitive impairment via the cAMP-CREB and JNK pathways in APPswe/PS1dE9 mouse model of Alzheimer's disease
Gu et al. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer’s disease
Liu et al. IRE1 signaling pathway mediates protective autophagic response against manganese-induced neuronal apoptosis in vivo and in vitro
Harraz et al. Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation
Buhner et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome
Xu et al. Role of autophagy in sevoflurane-induced neurotoxicity in neonatal rat hippocampal cells
Zhi et al. Paeoniflorin suppresses ferroptosis after traumatic brain injury by antagonizing P53 acetylation
Liu et al. Dopamine D2 receptor agonist bromocriptine ameliorates Aβ1-42-induced memory deficits and neuroinflammation in mice
Dai et al. Microglial responses and pain behaviors are exacerbated by chronic sleep deprivation in rats with chronic pain via neuroinflammatory pathways
Ma et al. A novel phthalein component ameliorates neuroinflammation and cognitive dysfunction by suppressing the CXCL12/CXCR4 axis in rats with vascular dementia
Cai et al. Curcumin prevents neurodegeneration by blocking HDAC6–NLRP3 pathway-dependent neuroinflammation in Parkinson’s disease
Feng et al. QBT improved cognitive dysfunction in rats with vascular dementia by regulating the Nrf2/xCT/GPX4 and NLRP3/Caspase-1/GSDMD pathways to inhibit ferroptosis and pyroptosis of neurons
Wu et al. Hydrogen mitigates brain injury by prompting NEDD4-CX43-mediated mitophagy in traumatic brain injury
Igarashi et al. Neuroprotective effect of oxytocin on cognitive dysfunction, DNA damage, and intracellular chloride disturbance in young mice after cranial irradiation
HK40040355A (en) Use of h3k9me3 modulation for enhancing cognitive function
HK40040355B (en) Use of h3k9me3 modulation for enhancing cognitive function
Zhao et al. Gastrodin ameliorated features of MPTP-induced Parkinson's disease via activating VMAT2 maintained dopamine homeostasis
Villalba Riquelme Investigating chemotherapy-induced peripheral neuropathies and its sexual dimorphism using an in vitro preclinical pain model
Wang et al. Schisandra chinensis lignans regulate immune-neuro crosstalk namely the “CB2R-BDNF” further achieving antidepression dependent on exosomes pathways
Tian et al. Biochanin a exerts neuroprotective effects in Parkinson's disease both in vivo and in vitro by improving mitochondrial dysfunction through the Sirt1 signaling pathway
Li et al. Neuroprotective effect of echinoside on MPTP-induced Parkinson's disease mouse model by activation of NRF2/HO-1 pathway
윤경노 Identification the skin-brain connection: Effects of UV exposure and dietary supplements on cognitive function and neurogenesis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant